With IPO Money, Neumora Eyes Deals as CEO Brings M&A Chops from Roles at AbbVie, JP Morgan

Neumora Therapeutics, a brain disease biotech born out of stitching together multiple neuroscience startups, is looking to replicate its original playbook by complementing its seven-drug pipeline with external assets thanks to a September IPO and $520 million balance sheet. “We are considering, and we are in discussions with either very late preclinical, IND-stage, or early clinical assets,” CEO and president Henry Gosebruch told Endpoints News in an in-person interview a day after the biotech disclosed its first quarterly update as a public company.

Read the full article: With IPO Money, Neumora Eyes Deals as CEO Brings M&A Chops from Roles at AbbVie, JP Morgan //

Source: https://endpts.com/neumora-seeks-deals-to-expand-neuro-pipeline-as-ceo-leverages-ma-experience

Scroll to Top